188 related articles for article (PubMed ID: 1657425)
1. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
de Jong S; Zijlstra JG; Mulder NH; de Vries EG
Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
3. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
de Jong S; Zijlstra JG; de Vries EG; Mulder NH
Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
[TBL] [Abstract][Full Text] [Related]
4. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
5. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line.
de Jong S; Timmer-Bosscha H; de Vries EG; Mulder NH
Int J Cancer; 1993 Jan; 53(1):110-7. PubMed ID: 8380054
[TBL] [Abstract][Full Text] [Related]
6. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
7. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
8. Fostriecin: a review of the preclinical data.
de Jong RS; de Vries EG; Mulder NH
Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
[TBL] [Abstract][Full Text] [Related]
9. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.
Versantvoort CH; Withoff S; Broxterman HJ; Kuiper CM; Scheper RJ; Mulder NH; de Vries EG
Int J Cancer; 1995 May; 61(3):375-80. PubMed ID: 7729950
[TBL] [Abstract][Full Text] [Related]
10. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
11. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
13. The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.
van der Graaf WT; Mulder NH; Meijer C; de Vries EG
Cancer Chemother Pharmacol; 1995; 35(4):345-8. PubMed ID: 7828280
[TBL] [Abstract][Full Text] [Related]
14. Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells.
Francis GE; Tejedor MC; Berney JJ; Chresta CM; Delgado C; Patel P
Leukemia; 1994 Jan; 8(1):121-8. PubMed ID: 8289477
[TBL] [Abstract][Full Text] [Related]
15. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
[TBL] [Abstract][Full Text] [Related]
17. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
